Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

Expanding brand awareness and access to HaluGen’s Psychedelics Genetic Test Kit Vancouver, British Columbia–(Newsfile Corp. – January 18, 2022) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, has announced an agreement with Psychedelics Today, LLC (“Psychedelics Today”) to help dri

Continue reading

Rapper Vic Mensah Arrested At Dulles Airport After Psychedelics Found

Dulles, Va. (WJZ) — Rapper Vic Mensah was arrested at Washington Dulles International Airport on Saturday after U.S. Customs and Border Protection officers found illicit narcotics in his baggage.

Victor Kwesi Mensah, 28, arrived at the airport via a flight from Ghana at about 7 a.m. on Saturday.

READ MORE: Mosby’s Attorney Says She Was Advised Retirement Account Withdrawals Were Permitted

Federal officers found 41 grams of liquid LSD, about 124 grams of Psilocybin capsules, 178 grams of Psilocybin gummies, and six grams of Psilocybin mushrooms concealed inside his luggage, according to a government press statement.

Metropolitan Washington Airport Authority Police officers confiscated the narcotics and charged Mensah with felony narcotics possession charges, federal officials said.

READ MORE: Ravens Re-Sign CB Kevon Seymour For 2022

He has been active in the music community since 2013. During that time he has partnered with artists like Kanye West and Sia.

Mensah has won three awards—an NAACP Image Award for outstanding new artist, a Grammy Award for best rap song, and an mtvU Woodie Award for best video.

Narcotics possession remains illegal under federal law and all travelers are subject to that law when departing and arriving at America’s ports of entry.

MORE NEWS: Some Struggle With Power Outages After Winter Storm Pelts Baltimore Region

CBP processes more than 650,000 travelers who arrived at airports, seaports and land border crossings per year, according to the press statement. Its officers arrest about 25 wanted criminals at ports of entry every day.

Psychedelic use is only “weakly” associated with psychosis-like symptoms, according to new research

People who take psychedelics are more likely to report psychosis-like symptoms, but this is largely explained by the presence of other mental health conditions and the use of other psychoactive drugs. This finding comes from a study published in the journal Scientific Reports, which further found improved evidence integration and greater flexibility of fear learning with psychedelic exposure.

Psychedelics are a class of drugs that produce hallucinogenic effects and can alter perception, mood, and cognition. The most common psychedelics include LSD (lysergic acid diethylamide), and psilocybin (“magic mushrooms”). In recent years, scientific studies have pointed to the potential therapeutic effects of these drugs, but surprisingly few studies have examined the possible harmful psychological effects.

While it has been suggested that psychedelics can provoke the “development of prolonged psychotic reactions”, larger studies have found no such evidence. A research team led by Alexander V. Lebedev wanted to re-explore this question among a young, healthy non-clinical population. They proposed that it would be easier to identify sub-clinical expressions of psychopathological traits, such as cognitive biases found along the schizophrenia spectrum, among a non-psychiatric group.

The researchers distributed a survey to 1,032 Swedish adults, of whom 701 were between the ages of 18 and 35 and had no psychiatric diagnoses and no history of brain trauma. The questionnaire included a measure of schizotypy — a personality trait that includes schizophrenia-like characteristics such as disorganized thinking and paranoid thoughts.

When comparing psychedelic users to non-users, average schizotypy scores among users were significantly higher, but the effect size was small. Furthermore, when looking exclusively at the subsample of healthy participants, the effect was only marginally significant. Finally, when taking co-occurring drug use into account, the effect of psychedelic use on schizotypy was no longer significant among either sample.

A follow-up survey among a subsample of 197 participants examined drug use patterns and found no evidence of heightened schizotypy among those with greater exposure to psychedelics. However, the use of stimulants such as cocaine or amphetamines was a robust predictor of higher schizotypy.

To explore causal effects, the researchers also conducted a behavioral study among a subset of 39 of the participants. The sample was made up of 22 psychedelic users and 17 age/sex-matched non-users. Participants completed a task to measure Bias Against Disconfirmatory Evidence (BADE) — a cognitive bias common along the schizophrenia spectrum. The task asked subjects to rate the plausibility of different interpretations of a scenario and assessed the BADE facet of Evidence Integration Impairment (EII) or “lack of ability to modify beliefs when facing new information.”

Surprisingly, psychedelic exposure actually predicted lower Evidence Integration Impairment scores, while the use of stimulants predicted greater Evidence Integration Impairment. These results, the authors say, “support the rationale of psychedelic-assisted therapy for non-psychotic psychiatric conditions characterized by overly fixed cognitive styles, such as, for example, depression.”

The participants also completed a reversal learning task that measured their fear responses to a conditioned stimulus that was sometimes presented with a mild electric shock, according to changing rules. After controlling for co-occurring drug use, people with greater overall psychedelic exposure showed higher sensitivity to instructed knowledge — suggesting greater flexibility of fear learning. Lebedev and his colleagues say that this may suggest that psychedelics can “augment top-down fear learning in a lasting way, which, in turn, may explain their particular efficacy in treating anxiety and trauma-related psychiatric disorders.”

Overall, the findings suggest only a weak link between psychosis-like symptoms and psychedelics. “Our analyses did not support the hypothesis that psychedelics may pose serious risks for developing psychotic symptoms in healthy young adults,” the authors say, although they specify that, “the lack of a strong relation between use of psychedelics and psychosis-associated symptoms does not preclude that such drugs are detrimental for individuals with a high risk of developing psychotic disorders—an important question that needs to be investigated in future studies.”

The study, “Psychedelic drug use and schizotypy in young adults”, was authored by Alexander V. Lebedev, K. Acar, B. Garzón, R. Almeida, J. Råback, A. Åberg, S. Martinsson, A. Olsson, A. Louzolo, P. Pärnamets, M. Lövden, L. Atlas, Martin Ingvar, and P. Petrovic.

Top Federal Drug Official Says ‘Train Has Left The Station’ On Psychedelics As Reform Movement Spreads

A top federal drug official says the “train has left the station” on psychedelics.

National Institute on Drug Abuse (NIDA) Director Nora Volkow said people are going to keep using substances such as psilocybin—especially as the reform movement expands and there’s increased attention being drawn to the potential therapeutic benefits—and so researchers and regulators will need to keep up.

The comments came at a psychedelics workshop Volkow’s agency cohosted with the National Institute of Mental Health (NIMH) last week.

The NIDA official said that, to an extent, it’s been overwhelming to address new drug trends in the psychedelics space. But at the same time, she sees “an incredible opportunity to also modify the way that we are doing things.”

“What is it that the [National Institutes of Health] can do to help accelerate research in this field so that we can truly understand what are the potentials, and ultimately the application, of interventions that are bought based on psychedelic drugs?” Volkow said.

The director separately told Marijuana Moment on Friday in an emailed statement that part of the challenge for the agency and researchers is the fact that psychedelics are strictly prohibited as Schedule I drugs under the federal Controlled Substances Act.

“Researchers must obtain a Schedule I registration which, unlike obtaining registrations for Schedule II substances (which include fentanyl, methamphetamine, and cocaine), is administratively challenging and time consuming,” she said. “This process may deter some scientists from conducting research on Schedule I drugs.”

“In response to concerns from researchers, NIDA is involved in interagency discussions to facilitate research on Schedule I substances,” Volkow said, adding that the agency is “pleased” the Drug Enforcement Administration recently announced plans to significantly increase the quota of certain psychedelic drugs to be produced for use in research.

“It will also be important to streamline the process of obtaining Schedule I registrations to further the science on these substances, including examining their therapeutic potential,” she said.

At Thursday’s event, the official talked about how recent, federally funded surveys showed that fewer college-aged adults are drinking alcohol and are instead opting for psychedelics and marijuana. She discussed the findings in an earlier interview with Marijuana Moment as well.

“Let’s learn from history,” she said. “Let’s see what we have learned from the marijuana experience.”

While studies have found that marijuana use among young people has generally remained stable or decreased amid the legalization movement, there has been an increase in cannabis consumption among adults, she said. And “this is likely to happen [with psychedelics] as more and more attention is placed on these psychedelic drugs.”

“I think, to a certain extent, with all the attention that the psychedelic drugs have attracted, the train has left the station and that people are going to start to use it,” Volkow said. “People are going to start to use it whether [the Food and Drug Administration] approves or not.

There are numerous states and localities where psychedelics reform is being explored and pursued both legislatively and through ballot initiative processes.

On Wednesday—during the first part of the two-day federal event that saw nearly 4,000 registrants across 21 time zones—NIMH Director Joshua Gordon stressed that his agency has “been supporting research on psychedelics for some time.”

“We can think of NIMH’s interests in studying psychedelics both in terms of proving that they work and also in terms of demonstrating the mechanism by which they work,” he said. “NIMH has a range of different funding opportunity announcements and other expressions that are priorities aimed at a mechanistic focus and mechanistic approach to drug development.”

Meanwhile, Volkow also made connections between psychedelics and the federal response to the coronavirus pandemic. She said, for example, that survey data showing increased use of psychedelics “may be a way that people are using to try to escape” the situation.

But she also drew a metaphor, saying that just as how the pandemic “forced” federal health officials to accelerate the development and approval of COVID-19 vaccines because of the “urgency of the situation,” one could argue that “actually there is an urgency to bring treatments [such as emerging psychedelic medicines] for people that are suffering from severe mental illness which can be devastating.”

But as Volkow has pointed out, the Schedule I classification of these substances under federal law inhibits such research and development.

The official has also repeatedly highlighted and criticized the racial disparities in drug criminalization enforcement overall.

Delaware Lawmakers File New Marijuana Legalization Bill With Key Equity Revisions

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

image

Canada approving psychedelics for therapy is a positive step, experts say – National | Globalnews.ca

A doctor and a psychologist say Health Canada’s move to allow physicians to request restricted psychedelic drugs for patients as part of their psychotherapy is a positive step toward transforming mental-health care.

image

But they say the recent change to the Special Access Program isn’t enough.

“We still have a huge amount of work to do because these medicines could really, really revolutionize the entire mental health-care field,” said Dr. Michael Verbora, who works as a medical director at the Field Trip Health therapy centre in Toronto.

“I don’t want to get too far ahead of where the science is … but I do really, really believe that if people have a process to start their own healing, it can lead to a much better world for most people.”

Read more:

‘People are desperate to heal’: The push for psychedelic-assisted therapy in Canada

Story continues below advertisement

Psychedelic assisted therapy involves ingesting consciousness-altering substances — including psilocybin, ketamine, LSD or MDMA (the active ingredient in ecstasy) — in a clinical setting as part of more traditional psychotherapy.

Health Canada has said requests will be considered on a case-by-case basis for a “serious or life-threatening condition” and where other conventional treatments have failed, are unsuitable for the patient or are not available in Canada.

Verbora said the change isn’t designed to have a wait list, because it’s meant for emergencies. Health Canada has said applications will be processed within two days, but it’s unclear when a decision would be made.

What it has done is streamline potential access to restricted drugs, Verbora said.

“Unfortunately, if you have a terminal illness, you don’t have much life left in you. You don’t have time to apply to the government and wait months to get an exemption.”


Click to play video: 'Psychedelic drugs offer hope for treatment-resistant mental illness'



2:16
Psychedelic drugs offer hope for treatment-resistant mental illness


Psychedelic drugs offer hope for treatment-resistant mental illness – Apr 5, 2021

Edmonton-based psychologist Brian Welling calls the approach “revolutionary.”

Story continues below advertisement

“This is the greatest leap forward in mental-health care since the invention of psychotherapy,” he said.

“I’ve used psychedelics many, many times. I didn’t have a serious or life-threatening condition, but for my own personal problems and part of my own spiritual journey, these experiences have been life-changing.

Verbora, who filed his first application on behalf of a patient this week, said one of the biggest challenges is that more physicians need education on psychedelic therapy.

“The responsibility really falls on the physician to do all the paperwork, which is like to write 100 prescriptions in the time that I do one of these applications,” he said. ”Then I’ll have to access the drug. I’ll have to store the drug. I’ll have to educate the patient on the drug.“

Read more:

Microdoses of psychedelic drugs can ease anxiety, depression: UBC study

Ronan Levy, co-founder of Field Trip Health, said most applications except the most severe will probably be rejected.

He said he hopes Health Canada’s criteria for approval of psychedelics expand in the future.

The government has said the regulatory amendment does not signal “an intent towards the decriminalization or legalization of restricted drugs.”

Story continues below advertisement

However, that conversation needs to start, said Verbora.

“We have a long way to go to help the millions of people around the world that unfortunately suffer from mental-health issues and (their) growing burden.”

All three men suggest that can happen by removing the stigma around psychedelics.

“When done in the right circumstances, with the proper oversight, with trained clinicians who can support the experience, the outcomes can be fantastic,” Levy said.

“That leads to people who have greater emotional resilience, people who are more able to adapt to circumstances like a global pandemic.”

© 2022 The Canadian Press

Peek Inside Philadelphia's Psychedelics Revolution

Longform

Tripping’s not just for deadheads anymore: Philly parents — and lots of other people — are learning that the secret to health, happiness and healing might just come from some formerly far-out drugs.


F Drugs 01REV | lucinate

The Philadelphia psychedelics movement: It’s not just for deadheads anymore. Illustration by Genie Espinosa

Like most working parents, Marissa has a lot to juggle — kids, her job as a nutritionist, her home outside of Philadelphia. And then there are the in-laws.

“I call my husband’s family a clan because there’s always somebody celebrating something or having a gathering,” she explains. That can be hard on her — she doesn’t feel the need to spend every weekend or even a full day hanging out with her husband’s extended family. “I would get anxious and bitchy,” she says of those long family sessions, and she’d be ready to go almost as soon as she arrived.

To deal, Marissa — who like most people in this story asked that we change her name for privacy’s sake — has found an unconventional solution, one that’s increasingly popular in both the Philadelphia region and the medical community.

When she’s feeling stressed or anticipating a big day with the family, Marissa takes a small nibble of a dried psilocybin mushroom and goes about her day. She’s one of many people turning to psychedelic drugs — to help manage stress, trauma and, yes, family. Some people, like Marissa, take small doses based on their own internet research, while others take larger doses in more formal settings. All of them say the experience provides them with relief they couldn’t find anywhere else.

“Having kids was the hardest thing I’ve ever done,” Marissa, the mom of two daughters, explains. “I’m kind of joking, but microdosing helps me be the mom that I want to be.”

In another time, not that long ago, partaking in psychedelic drugs was for hippies and free spirits — a small slice of the population in a city as big as Philadelphia. But with the resurgence and endorsement in popular culture of drugs like MDMA, psilocybin, ketamine and LSD, what only recently seemed countercultural is suddenly becoming mainstream.

The growing national psychedelic movement has been spurred on by mainstream writers like Michael Pollan, documentaries on Netflix, and larger political shifts, like the legalization of marijuana in 18 states and D.C. In the past few years, psychedelics have broken through to an audience of buttoned-up skeptics as a potential treatment for all kinds of things — from PTSD to depression to anxiety and more. From underground guided mushroom trips to ketamine-assisted psychotherapy sessions to clinical trials for therapy-assisted MDMA treatments, all with a range of intents and goals, the psychedelic movement is growing at an exponential pace.

No place is more primed for this latest wave of mind expansion than Philly, where doctors, lawyers, parents, teachers, and everyone in between is turning to psychedelics as a means to process whatever the hell happened these past few years. After a seemingly endless pandemic marked by trauma and loss, more people than ever are seeking help in the form of plant medicine in the City of Brotherly Love.

When Marissa attended Drexel in the ’90s, she considered so-called “magic mushrooms” a recreational drug, one she’d take maybe once a year, the way her friends would occasionally indulge in ketamine at raves. But that was a long time ago. Back then, she never heard about anyone doing drugs to heal from trauma or deal with life’s daily stresses. “It was just something people did for fun — there was no therapeutic effect to it,” she says.

F Drugs 05 | lucinate

Illustration by Genie Espinosa

Being a mom, though, was extremely challenging. Through some online research, she learned about microdosing, an informal practice whereby you take a small dose of a psychedelic — typically psilocybin mushrooms, frequently powdered and stored in capsules — every few days. She hoped it might help her deal with the stress of parenthood and family life.

A hemp grower in Pennsylvania steered her to someone who was growing magic mushrooms and selling them in a professionally sealed bag — “It’s the first time I didn’t get them in a rolled-up plastic baggie” — for between $200 and $250 an ounce, about a month’s supply.

Marissa says she doesn’t notice physical effects, like the stereotypical walls melting or bright colors or hallucinations you see characters experience in movies. But the emotional impacts on her have been huge. “I have found the biggest effect for this microdosing has been on my patience with my family and my daughters,” she says.

She’s noticed a ripple effect, too: “If I have more patience, then my husband is much more patient with me, and that enhances our relationship, which means I can be more present with my daughters.”

Other local residents are using microdosing to seek relief from even bigger issues. Paul, a 34-year-old nursing student in Philly, was grieving after his brother died by suicide last year. To deal with the trauma, he and his mom, both in deep pain, explored talk therapy. But they couldn’t find an affordable option. “I was looking for other alternatives that weren’t dangerous,” Paul says.

First, he turned to marijuana, but he found it made him sleepy, and he would snack too much. “One of my friends was telling me about microdosing with ’shrooms,” he recalls. It sounded good to him, so he asked the person he bought weed from if she had mushrooms. What do you know? She did.

He ground up a small amount of mushrooms, put the powder in capsules, and would take one once a day or every other day. “There’s not much information out there on how much to take,” he says, so he just poked around online and dosed himself.

In four or five months of microdosing, Paul says, he’s noticed “a complete change in my mind. My anxiety has subsided significantly. I feel like the best version of myself. I obviously still have moments of anxiety. It’s not like I’m completely cured. But I feel much better in general.”

Paul’s partner tells him he’s become a much more polite person since starting his microdosing. “Just because of the traumatic stress that I’ve been going through, it’s hard for me to be nice,” he says. “There’s always something going on, and this made me more patient.”

While microdosing can feel like a less intimidating way to test the efficacy of psychedelics for mental health, it’s only one of many options people are seeking, and in more legitimate medical settings, it has its detractors. Hannah McLane, one of the leaders of Philly’s movement toward greater access to psychedelic drugs and the founder and executive director of SoundMind, the first psychedelic-assisted psychotherapy treatment center in Philly, says the idea of microdosing a psychedelic every few days can miss the larger intention of the medicine. If we want to heal from trauma and move forward from emotional struggles, she says, small daily doses won’t necessarily achieve that goal.

“Microdosing isn’t particularly innovative; it’s just what people are used to,” McLane says — a way to make the larger treatment more palatable to the masses. Since microdosing can feel similar to taking an antidepressant or anxiety med every day — just more natural, so to speak — there’s a risk that psychedelic medicine could become just one more pharmaceutical intervention, a pattern that many in the psychedelic movement hope to avoid. “Higher doses sound a little bit scary, and everyone’s afraid they’re going to run down the street naked. And it’s like, no, the scary part is actually where the healing comes,” says McLane. “You have to go into the part of your mind that you didn’t go into before.”

Research on microdosing mushrooms is limited, and though there are more in-depth studies on the benefits of longer, more dedicated psilocybin trips for treatment-resistant depression and PTSD — many of them conducted by the Johns Hopkins Center for Psychedelic and Consciousness Research — the drug’s status as a Schedule 1 drug, which means the FDA classifies it as having a high potential for abuse, makes studying its short- and long-term effects difficult. But change may be coming: In November of 2020, Oregon became the first state to legalize psilocybin for anyone over the age of 21, with a few caveats. To gain access to the drug, you must pass a screening test, and it must be administered in a licensed facility.

This change follows the FDA approval of esketamine, a ketamine nasal spray, for treatment-resistant depression. Since then, ketamine clinics have popped up everywhere, and savvy entrepreneurs have, unsurprisingly, built Silicon Valley start-ups with fancy websites and silly names like Mindbloom and Field Trip to capitalize on the movement. Fittingly, Philadelphia’s ketamine-assisted therapy clinic is a little less corporate and more down-to-earth, located in the heart of West Philly.

“I think Philly is special,” says the SoundMind Center’s McLane. “We have a history of innovation and art, and, you know, we’re the original capital of the country.” For Philly to be the next spot where people feel safe using psychedelics to explore trauma and pain makes sense, McLane says: “If you want a place that is a snapshot of American culture — the good and bad parts about American culture all contained within one little city? It’s Philly.”

The SoundMind Center looks like a lot of other houses in West Philly. It’s one half of a twin, with a big front porch and austere pillars in that classic brown. But at the treatment center where McLane, a physician and psychotherapist who trained at Penn, Temple, Harvard and Brown, is running the show, there’s a lot going on behind those doors that looks like nothing else in the city.

SoundMind is a psychedelic healing center and educational facility where patients experiencing debilitating symptoms impacting their mental health, like depression, anxiety and PTSD, can sit with a trained therapist during a ­ketamine-assisted psychotherapy session. Ketamine — ­technically the same ketamine that Marissa’s club friends would do in the ’90s — has been legal as an anesthetic for more than 50 years, but only in the past decade has research been done on its potential benefits for mental health. Ketamine produces short trips — between 45 and 90 minutes — so it’s an easier sell than using mushrooms or other psychedelics for a traditional medical community that’s only just dipping its toes into administering psychedelic medicine.

Ketamine isn’t McLane’s first choice of drug to work with, but it’s the one she’s got right now. While psilocybin has been legalized in Oregon and MDMA-assisted therapies are in trial stages for specific conditions like deep trauma and PTSD in other states, she anticipates it could be several years before the latter is approved for the same kinds of treatment that ketamine is.

There are more than 600 people on the SoundMind wait list, all hoping to see whether psychedelics can alleviate their depression, anxiety and/or PTSD. Many of them suffer from trauma caused by the pandemic. Out of all the treatment options, McLane is most excited by the promise of MDMA.

“What MDMA does is circumvent the amygdala, which is the fear center in the brain,” she explains. “So you’re essentially able to engage with a trauma memory or a difficult memory without dissociating. And that is the way you can heal.” In clinical trials for MDMA-assisted therapy, patients sit for eight hours, typically wearing an eye mask and listening to music, with two therapists who check in while the patients talk about what they are experiencing and feeling. (MDMA is a very talkative drug, so that inevitably happens quickly.)

“The gold standard for therapists working in trauma is prolonged exposure therapy, in which you’re asking someone to tell the trauma over and over again,” McLane says. “And they have about a 40 percent dropout rate, because it’s really uncomfortable.” In MDMA-assisted therapy, patients establish an intention (like processing a difficult life event or unshakable emotion) beforehand and allow that subject to naturally come up during the trip, then are usually better able to engage with feelings than they would be in traditional therapy. “Sometimes it comes up two hours in or four hours in,” McLane says. “You can’t always predict how someone’s going to get to the difficult memory. Sometimes it seems like a totally random other story.” Because of this, McLane says, the patient is “able to stay present, go into the memory, and feel it.”

Then comes the integration.

You’ll find people in the psychedelic community use the word “integration” a lot. In a more clinical setting, the term can describe the sessions that follow a psychedelic-assisted trip, during which clinicians have their patients sit and talk through what they learned on their journeys.

Natalie Ginsberg, the director of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies, explains it to me in meme form over the phone before texting me an image: a withered man walking through a tunnel, looking sad and dejected. “I should sit with more medicine,” he thinks. A great dark shadow is crawling behind him with a pained look on its face, begging, “Bro, fucking integrate me.” The point: Taking psychedelic medicine may be the exciting or thrilling part, but actually putting that learning into practice on a day-to-day basis isn’t always easy.

Using psychedelics to deal with traumatic experiences, whether the death of a loved one or the anxieties of parenting — or even to get in touch with a deeper sense of self — isn’t new. But access to both formal and informal networks that guide people in their use and thus help them disinvest from the traditional pharmaceutical industry is growing. The Philadelphia Psychedelic Society currently has a wait list in the hundreds of people eager to be led on a psychedelic trip by a trained facilitator.

F Drugs 02 | lucinate

Illustration by Genie Espinosa

At the same time, those in the movement are aware that the treatments are less accessible to those in the region who might need them most. “Black, Indigenous, people of color, LGBTQIA-plus people, those who are neurodiverse — we all experience higher rates of mental illness yet have lower access to care,” says Aubrey Howard, BIPOC protocol coordinator at SoundMind, which seeks to make these therapies more available to traditionally marginalized communities. “There is definitely a barrier to entry for people of color when talking about wellness or holistic medicine or psychedelic medicine.” In other words, according to Natalie Ginsberg: “It’s generally much safer for white folks to speak publicly about drugs and drug use.” (Not to mention to use. People of color are still criminalized more often for drug use, and by extension, trust levels around these supposedly wonderful natural, still largely illegal medicines are low in marginalized communities.)

If this movement is going to succeed, Howard says, there has to be access for all, not just for those who have the time, space and money to get in touch with their inner selves for a day. “I feel that these medicines have immense potential to be agents of change in America and over all the world,” Howard says. “We don’t want to see the same thing happen with psychedelics that happened with the cannabis movement, where it’s a very small group of people, probably white, probably wealthy, who are the ones given access.”

Until a wider range of psychedelics becomes available in formal settings, there are those who are experimenting informally. Laura, a bodywork teacher in Kensington, was at the beach in the summer of 2020 when she took mushrooms for the first time since high school — not a microdose to take the edge off with her kids, but a full six-hour dose with a few friends. She hadn’t been around a lot of people since COVID, and she was able to take some time away from her six-year-old and her husband to see what the recent attention to psychedelics was all about.

“It was an intensification of a time that was already really intense,” Laura recalls.

After her trip (both physical and metaphysical) to the beach, Laura says, she sensed herself closing off: “I felt frickin’ fried. I was exhausted. That was a whole darn lot. I think sometimes it can be an ongoing enlivening, and sometimes it can be letting in a little bit more than my nervous system can handle.”

But that’s all part of the process, she says. And she’ll definitely be taking a trip again. “I think psychedelics can help us make more contact and peace inside ourselves so that we can have more contact and peace with our kids,” she says. Even though she’s not planning on doing mushrooms more than once a year, she sees the practice as a potential annual event. The substance could help heal some of our “collective deep trauma around COVID,” she says.

Of the dozens of people I spoke to for this story, almost all were kind and open, speaking of their experiences with psychedelics in almost mythically positive ways. The reasons they got into doing psychedelics were all different: stress relief, childhood trauma, depression, grief, for fun, to relax. There were people whose experiences were challenging, others who took psychedelics daily, still others who were working within a more formal framework — like the ones SoundMind is working to further popularize — by taking the drugs alongside psychotherapy once and never again.

The connecting factor among them all: Nothing else had worked or had been nearly as effective in delivering what they were searching for.

“It’s hard to explain in words,” one frequent psilocybin user, who had repressed memories of his childhood trauma, tells me. “The body remembers,” he says, so in his 30s, memories started to come back to him. “Microdosing helped me put language to a lot of those experiences that I would have trouble remembering,” he says. “It definitely helps on the day-to-day in creating new neurological pathways, opening up past wounds that are subconscious.”

But it’s not only been helpful for dealing with deeper trauma. Sometimes, it’s just what he needs to feel lighter, to lift some of the heaviness his past has pushed onto him: “At this point in time, with how my life has been going, I’ve never felt better in my entire life.”

Meanwhile, Laura, who first reexperienced psychedelics on that beach two summers ago, has seen them used more frequently among her group of parents. When she and her friends get a chance to step away from parenting duty, they’ll do psychedelics together, as a “getaway.” She’s especially appreciative of how mushrooms have affected her husband’s parenting: “I have seen him able to connect with our kid in a way that seems more expansive, having more presence,” she says.

“There’s an articulation and a brightening” that happens while she’s on mushrooms, Laura explains, and that clarity and liveliness help her interpret things in ways she never thought to before. “I really honor the wisdom of psychedelic mushrooms and want that to be an ongoing current in my life,” she says, adding that she hopes the psychedelics trend will continue to grow: “It happening anywhere would be good for everywhere. But if it did happen here, I would feel a little more Philly pride.”

The Dosing DL

Get to know the four drugs in the current psychedelic movement.

Magic mushrooms

Can help with: Depression, lulls of creativity

In supervised settings, these natural hallucinogens are now considered some of the safest psychedelics. Researchers at Johns Hopkins Medicine found psilocybin—the chemical compound in magic mushrooms—helped relieve major depression in patients, while social users say they feel more creative, solution-savvy and self-reflective.

LSD

Can help with: Enhancing mood and productivity

Aside from inspiring Steve Jobs to create Apple’s minimalist designs, LSD microdosing is said to have antidepressant-like qualities, elevating mood and catalyzing feelings of bliss without totally altering the senses the way higher doses often do. Users also claim the drug helps boost their focus, productivity and energy levels.

MDMa

Can help with: PTSD, social interaction

MDMA, or Ecstasy, can help folks open up to and connect with others and ease social anxiety, especially for adults living with autism, according to Matthew Johnson, a psychedelics researcher and scientist. When combined with psychotherapy, the drug has been reported
to assist those with PTSD in revisiting and processing traumatic experiences without becoming fearful or emotionally overwhelmed.

Ketamine

Can help with: Treatment- resistant depression, general perspective-shifting

Hannah McLane, of SoundMind in West Philly, says ketamine prompts a kind of disassociation that can help folks “gain perspective of their lives” and work through anxiety or trauma more objectively. In 2019, the FDA approved a version of ketamine for treatment-resistant depression, and a wearable ketamine pump intended to fight opioid addiction will soon head to clinical trials. —Laura Bryzski

For more on Philly’s Psychedelic revolution, check out these articles on the benefits of microdosing THC and the legalization of psychedelics in Pennsylvania.

Published as “Philadelphia’s Psychedelic Revolution” in the January 2022 issue of Philadelphia magazine.

Morning glories may be a source of new psychedelics and medicines

With their beautiful blue trumpet bells unfurling to greet the sun, the morning glory adds a splash of color to the start of your day. 

Its seeds, however, may do a bit more than that — new research has found that, thanks to a symbiotic relationship with a fungus, this common flower may be a source for new psychedelic drugs.

The flower-fungus relationship can lead to the creation of compounds called ergot alkaloids. Ergot alkaloids have been used to treat Parkinson’s disease and brutally painful migraine and cluster headaches for decades. But they’re also closely related to LSD.

Examining the seeds of morning glories taken from collections around the globe, researchers from Tulane, Indiana University, and West Virginia University found that a quarter of the 210 morning glory species they examined had some form of ergot alkaloid in their seeds.

“We have known a lot about the fungal alkaloid chemistry and its effects on the mind and body for [a] long time,” Tulane plant and fungal biologist Keith Clay said

This new study is the first to show just how intermingled morning glory and egot evolution is — a relationship that is “manifested by different mixtures and concentrations of ergot alkaloids across the morning glory evolutionary tree.”

New research has found that, thanks to a symbiotic relationship with a fungus, the common flower may be a source of new psychedelic compounds called ergot alkaloids.

A symbiotic relationship: A deal that benefits both partners of two different species is known as symbiotic. 

In some cases, that symbiotic relationship can be encoded in evolution, the authors explain in their study, published in Communications Biology. Organisms that help another one out may get a leg up in the reproduction game, like wasps who harbor bacteria that produce compounds which help fight off infection in their larvae — larvae that have inherited the microbial symbiote from their mother.

Some plants have a similar relationship with fungi. In certain grasses, the ergot fungus — cause of Saint Anthony’s Fire — creates ergot alkaloids that don’t stay contained in the fungus’s thready, root-like structures, but can actually be passed down in the seeds. 

These ergot alkaloids make the plants less fun to eat, and everybody wins.

Some species of morning glory have forged a similar relationship. The ergot alkaloids contained in their seeds “have been of longstanding interest given their toxic effects on humans and animals, medical applications and psychoactive properties,” the researchers wrote. 

One ergot alkaloid, lysergic acid, is particularly famous: it’s the inspiration behind LSD, a synthetic derivative.

Ergot alkaloids inspired LSD, and treat migraines and Parkinson’s.

New potential: Naturally occurring ergot alkaloid compounds have long been used among Indigenous American communities for their mental and physical effects. 

Finding a trove of new ergot alkaloid compounds means potential for new psychedelics, which in turn may end up being useful as mental health therapies or perhaps anti-inflammatories.

The new compounds may have uses beyond the psychedelic. Currently, ergot alkaloids’ potential to constrict the blood vessels around the head also make them cluster and migraine headache medications, while their ability to goose nerve cells in a way similar to dopamine means they can be used as a treatment for Parkinson’s.

The researchers reported 36 new ergot alkaloid compounds, suggesting to them that even more examples of the symbiosis will be uncovered with continuing research.

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at tips@freethink.com.